View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 12, 2022

Vertex signs agreement to acquire ViaCyte for $320m

Through the acquisition, Vertex plans to advance its potentially curative VX-880 programmes in T1D.

Vertex Pharmaceuticals has signed a definitive agreement for the acquisition of biotechnology company ViaCyte in a deal totalling $320m in cash.

ViaCyte focuses on offering new stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D).

Through the acquisition, Vertex plans to advance its potentially curative VX-880 programmes in T1D.

VX-880 is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy of Vertex for T1D.

It has attained proof-of-concept with favourable safety and efficacy data from an ongoing Phase I/II clinical trial which is currently enrolling and dosing participants.

Vertex Pharmaceuticals CEO and president Reshma Kewalramani said: “VX-880 has successfully demonstrated clinical proof of concept in T1D, and the acquisition of ViaCyte will accelerate our goal of transforming, if not curing T1D by expanding our capabilities and bringing additional tools, technologies and assets to our current stem cell-based programmes.”

The ViaCyte takeover offers Vertex complementary assets, expertise and technologies, including further human stem cell lines.

Vertex will also gain access to intellectual property around stem cell differentiation and Good Manufacturing Practice (GMP) manufacturing sites for cell-based therapies that could expedite its T1D programmes.

Furthermore, through the takeover, Vertex will obtain access to new hypoimmune stem cell assets under the ViaCyte-CRISPR Therapeutics partnership.

ViaCyte president and CEO Michael Yang said: “ViaCyte’s commitment to finding a functional cure for T1D is shared by Vertex, and this acquisition will allow Vertex to deploy ViaCyte’s tools, technologies and assets toward the development of Vertex’s multiple cell replacement therapy approaches designed to reduce the burden of millions of people living with T1D worldwide.”

Subject to necessary conditions, the transaction is anticipated to conclude later this year.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology